Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

874P - Concurrent chemoradiation with cisplatin alone versus cisplatin and capecitabine in treatment of locally advanced head and neck cancer

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Head and Neck Cancers

Presenters

Abhishek Krishna

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

A. Krishna

Author affiliations

  • Radiation Oncology Department, Father Muller Medical College, 575003 - Mangalore/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 874P

Background

Concurrent chemoradiotherapy is the standard treatment of locally advanced head and neck cancers. The objective of this study was to assess the locoregional response rates and acute toxicity in patients with locally advanced head and neck carcinoma treated with concurrent chemoradiation with cisplatin versus cisplatin and capecitabine.

Methods

A total of 108 patients meeting the inclusion criteria were included in the study and randomly assigned to 2 arms of 55 patients each. Patients in Arm A were treated with chemoradiation to a dose of 70 Gy with weekly Inj. cisplatin 40mg/m2. Patients in Arm B were treated with chemoradiation to a dose of 70 Gy with weekly Inj. cisplatin 40mg/m2 and T. Capecitabine 500mg/m2 twice daily along with RT. Locoregional response rates were assessed clinically and radiologically 6 weeks after concurrent chemoradiotherapy. The toxicity profile of the treatment was assessed with RTOG acute morbidity scoring criteria and CTCAE Version 4. Statistical evaluation was done with mean, percentage and frequency using Chi-Square, Student’s t-test.

Results

A total of 50 patients in each arm completed the study and were available for analysis. In the cisplatin-only arm, 65% of patients had complete response and 35% had partial response. In the cisplatin and capecitabine arm 74% of patients had complete response and 26% had partial response. In arm A, grade 3 mucositis were seen in 9 patients, grade 3 skin reactions in 5 patients. None of the patients had grade 3 or more diarrhea whereas 3 patients had grade 3 vomiting. In arm B, grade 3 mucositis were seen in 16 patients, grade 3 skin reactions in 8 patients. 4 patients had grade 3 diarrhea whereas 5 patients had grade 3 vomiting. None of the patients had hand-foot syndrome or renal toxicities

Conclusions

Concurrent chemoradiation with cisplatin and capecitabine in locally advanced head and neck cancer is a better regimen with higher complete response rates compared to chemoradiation with cisplatin alone with manageable toxicities.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.